Dexcel Pharma

Company Overview

Snapshot

Founded in January 1965 by Dan Oren, Dexcel Pharma operates with over 500 employees. The company specializes in the discovery, development, manufacture, and commercialization of pharmaceutical products. A key milestone for the company was the agreement signed in April 2014 with Kitov Pharma for a hypertension drug.

Business overview

Dexcel Pharma is a pharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative pharmaceutical products. The company leverages its proprietary controlled-release technologies to develop novel formulations of existing molecules and complex generic drugs. It aims to provide significant clinical benefits for patients with chronic diseases, exemplified by its PerioChip product for gum disease. Dexcel Pharma serves markets in the U.S. and the EU, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology.

Strategic signal

In April 2014, Dexcel Pharma entered into a strategic deal with Kitov Pharma concerning a hypertension drug. This collaboration signals Dexcel Pharma's ongoing engagement in developing and commercializing pharmaceutical solutions for major therapeutic areas, demonstrating its commitment to expanding its product portfolio and market reach through partnerships.

Company Intelligence Q&A

When was Dexcel Pharma founded?

Dexcel Pharma was founded in January 1965.

Who founded Dexcel Pharma?

Dexcel Pharma was founded by Dan Oren.

What is Dexcel Pharma's primary focus?

Dexcel Pharma focuses on the discovery, development, manufacture, and commercialization of innovative pharmaceutical products using proprietary controlled-release technologies.

What significant deal did Dexcel Pharma sign in 2014?

In April 2014, Dexcel Pharma signed a deal with Kitov Pharma for a hypertension drug.

What are some of Dexcel Pharma's key products?

Dexcel Pharma's key products include Omeprazole, PerioChip, and Deximune.